Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic ...
Medscape

UK Approves New JAK Inhibitor for Severe Alopecia

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on ...
Yahoo

Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion

FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly announced on Friday safety ...
Monthly Prescribing Reference

Rezpegaldesleukin Fast Tracked for Severe to Very Severe Alopecia Areata

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...
Healio

Topline data show upadacitinib improved severe alopecia

Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor under investigation for the treatment of multiple dermatologic indications ...
Monthly Prescribing Reference

Leqselvi Now Available for Severe Alopecia Areata

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...
Healio

‘We should not be waiting’: Early baricitinib therapy benefits teens with alopecia

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Baricitinib maintained hair regrowth among adolescents ...
Seeking Alpha

Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®

TORONTO, Jan. 14, 2026 /CNW/ - Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant ® for severe alopecia areata to its public drug ...
AOL

Alopecia Universalis: What to Know About Complete Hair Loss

Alopecia universalis (AU) is a rare autoimmune condition that involves complete loss of hair on your face, scalp, and body. The earlier you seek treatment, the better your chances of maintaining your ...
The American Journal of Managed Care

Moderate to Severe Alopecia Areata Linked to Higher Risk of Atopic Dermatitis Diagnosis

Claims-based MarketScan analyses (>11,000 patients) showed moderate-to-severe alopecia areata carried higher atopic dermatitis risk than mild disease (adjusted HR 1.8; 95% CI 1.1–2.8). Baseline atopic ...
WebMD

How Olumiant Works for Alopecia

Alopecia areata causes hair loss on the scalp or other body parts such as the eyebrows. New treatments like Olumiant offer hope for some people. This FDA-approved medicine works in unique ways to help ...